Neuroblastoma Market Symptoms, Treatment, Analysis, Overview and Pipeline Review, H1 2016

Neuroblastoma Market Size, Symptoms, Overview and
Pipeline Review, H1 2016
Summary
Global Markets Direct's, 'Neuroblastoma - Pipeline Review, H1 2016', provides an overview of the Neuroblastoma
pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Neuroblastoma,
complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration
(RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its
complete research and development history and latest news and press releases. Additionally, the report provides
an overview of key players involved in therapeutic development for Neuroblastoma and features dormant and
discontinued projects.
For More Information, Visit @ http://www.radiantinsights.com/research/neuroblastoma-pipeline-review-h12016
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and
nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's
proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university sites and industry-specific third party sources.
Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that
all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes
ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision
making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Neuroblastoma
- The report reviews pipeline therapeutics for Neuroblastoma by companies and universities/research institutes
based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till
discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description,
descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Neuroblastoma therapeutics and enlists all their major and minor
projects
- The report assesses Neuroblastoma therapeutics based on drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Neuroblastoma
Reasons To Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain
competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Neuroblastoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neuroblastoma pipeline depth and focus of
Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most
attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove
them from pipeline
Request Sample Copy of This Report @ http://www.radiantinsights.com/research/neuroblastoma-pipelinereview-h1-2016/request-sample
Table of Contents
Table of Contents 2
Introduction 6
Neuroblastoma Overview 7
Therapeutics Development 8
Neuroblastoma - Therapeutics under Development by Companies 10
Neuroblastoma - Therapeutics under Investigation by Universities/Institutes 14
Neuroblastoma - Pipeline Products Glance 16
Neuroblastoma - Products under Development by Companies 19
Neuroblastoma - Products under Investigation by Universities/Institutes 24
Neuroblastoma - Companies Involved in Therapeutics Development 25
Neuroblastoma - Therapeutics Assessment 71
Drug Profiles 87
Neuroblastoma - Recent Pipeline Updates 263
Neuroblastoma - Dormant Projects 360
Neuroblastoma - Discontinued Products 363
Neuroblastoma - Product Development Milestones 364
Appendix 371
For More Information, Visit @ http://www.radiantinsights.com/research/neuroblastoma-pipeline-review-h12016
About Us:
Radiant Insights Inc. is a platform for companies looking to meet their market research and business intelligence
requirements. We assist and facilitate organizations and individuals procure market research reports, helping them
in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries
and a host of micro markets. In addition to over extensive database of reports, our experienced research
coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research
solutions.
Contact Details:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
28 2nd Street,
Suite 3036 San Francisco,
CA 94105 United States
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Website: http://www.radiantinsights.com/
Email: [email protected]
Visit our Blog: http://chemicalsandmaterialsri.blogspot.com